MX2018000278A - Terapia de receptores quimericos de puntos de control inmunitarios. - Google Patents
Terapia de receptores quimericos de puntos de control inmunitarios.Info
- Publication number
- MX2018000278A MX2018000278A MX2018000278A MX2018000278A MX2018000278A MX 2018000278 A MX2018000278 A MX 2018000278A MX 2018000278 A MX2018000278 A MX 2018000278A MX 2018000278 A MX2018000278 A MX 2018000278A MX 2018000278 A MX2018000278 A MX 2018000278A
- Authority
- MX
- Mexico
- Prior art keywords
- therapy
- chimeric antigen
- immune checkpoint
- antigen receptors
- transmembrane proteins
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 title 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 102000035160 transmembrane proteins Human genes 0.000 abstract 2
- 108091005703 transmembrane proteins Proteins 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 1
- 108091008042 inhibitory receptors Proteins 0.000 abstract 1
- 230000004068 intracellular signaling Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- C12N9/1211—Thymidine kinase (2.7.1.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
En algunos aspectos, las modalidades se relacionan con composiciones y métodos relacionados con proteínas quiméricas transmembranales. Las proteínas quiméricas transmembranales pueden comprender al dominio extracelular de un receptor inhibidor, y un dominio de señalización intracelular que puede activar una respuesta inmune.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562186108P | 2015-06-29 | 2015-06-29 | |
PCT/US2016/040010 WO2017004150A1 (en) | 2015-06-29 | 2016-06-29 | Immune checkpoint chimeric antigen receptors therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018000278A true MX2018000278A (es) | 2018-03-08 |
Family
ID=57609024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018000278A MX2018000278A (es) | 2015-06-29 | 2016-06-29 | Terapia de receptores quimericos de puntos de control inmunitarios. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20180185434A1 (es) |
EP (1) | EP3313892A4 (es) |
JP (1) | JP2018520679A (es) |
KR (1) | KR20180038447A (es) |
CN (1) | CN108137707A (es) |
AU (1) | AU2016285859A1 (es) |
CA (1) | CA2991040A1 (es) |
HK (2) | HK1254820A1 (es) |
IL (1) | IL256643A (es) |
MA (1) | MA42272A (es) |
MX (1) | MX2018000278A (es) |
WO (1) | WO2017004150A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11478548B2 (en) | 2015-07-08 | 2022-10-25 | The Johns Hopkins University | Marrow infiltrating lymphocytes (MILs) as a source of T-cells for chimeric antigen receptor (CAR) therapy |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2948544A4 (en) | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
CA2948462A1 (en) | 2014-05-15 | 2015-11-19 | National University Of Singapore | Modified natural killer cells and uses thereof |
EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
US10590169B2 (en) * | 2015-12-09 | 2020-03-17 | Virogin Biotech Canada Ltd | Compositions and methods for inhibiting CD279 interactions |
JP7250519B2 (ja) * | 2016-03-23 | 2023-04-03 | ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト (ゲーエムベーハー) | Pd-1及び4-1bbの融合タンパク質 |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
KR20180128496A (ko) | 2016-04-22 | 2018-12-03 | 오비아이 파머 인코퍼레이티드 | 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법 |
TWI752988B (zh) | 2016-07-27 | 2022-01-21 | 台灣浩鼎生技股份有限公司 | 免疫性/治療性聚醣組合物及其用途 |
EP3491026A4 (en) | 2016-07-29 | 2020-07-29 | OBI Pharma, Inc. | HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS |
CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
AU2017382243A1 (en) * | 2016-12-22 | 2019-05-02 | Windmil Therapeutics, Inc. | Compositions and methods for modulating the immune system |
CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
BR112019020001A2 (pt) | 2017-03-27 | 2020-04-28 | Nat Univ Singapore | linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais |
WO2018191490A1 (en) * | 2017-04-13 | 2018-10-18 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy |
JP2022513687A (ja) * | 2018-11-30 | 2022-02-09 | ウィンドミル セラピューティクス インコーポレイテッド | キメラ抗原受容体(car)を発現する骨髄浸潤リンパ球(mil)、その製造方法および治療における使用方法 |
CN113766956B (zh) | 2019-03-05 | 2024-05-07 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
WO2022098985A1 (en) * | 2020-11-05 | 2022-05-12 | Windmil Therapeutics, Inc. | Glioblastoma specific marrow infiltrating lymphocytes and uses thereof |
US20240139301A1 (en) * | 2020-11-19 | 2024-05-02 | Obi Pharma, Inc. | Active cancer immunotherapy by immune modulation via globo series antigens |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012290342A1 (en) * | 2011-07-29 | 2014-01-30 | The Trustees Of The University Of Pennsylvania | Switch costimulatory receptors |
JP6074435B2 (ja) * | 2011-10-26 | 2017-02-01 | ナショナル キャンサー センター | 変異ctla4遺伝子移入t細胞及びこれを含む抗がん免疫治療用組成物 |
AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
CA2912375C (en) | 2013-05-13 | 2023-03-14 | Cellectis | Methods for engineering highly active t cell for immunotherapy |
JP6793902B2 (ja) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | 調節可能キメラ抗原受容体 |
US20170209492A1 (en) * | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
AU2015311761B2 (en) | 2014-09-04 | 2020-11-12 | The Johns Hopkins University | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions |
CN115925971A (zh) * | 2015-06-19 | 2023-04-07 | 塞巴斯蒂安·科博尔德 | Pd-1-cd28融合蛋白及其在医学中的用途 |
-
2016
- 2016-06-29 JP JP2017568207A patent/JP2018520679A/ja active Pending
- 2016-06-29 CN CN201680048831.3A patent/CN108137707A/zh active Pending
- 2016-06-29 KR KR1020187002679A patent/KR20180038447A/ko not_active Application Discontinuation
- 2016-06-29 CA CA2991040A patent/CA2991040A1/en not_active Abandoned
- 2016-06-29 MX MX2018000278A patent/MX2018000278A/es unknown
- 2016-06-29 MA MA042272A patent/MA42272A/fr unknown
- 2016-06-29 EP EP16818647.6A patent/EP3313892A4/en not_active Withdrawn
- 2016-06-29 US US15/740,981 patent/US20180185434A1/en not_active Abandoned
- 2016-06-29 WO PCT/US2016/040010 patent/WO2017004150A1/en active Application Filing
- 2016-06-29 AU AU2016285859A patent/AU2016285859A1/en not_active Abandoned
-
2017
- 2017-12-28 IL IL256643A patent/IL256643A/en unknown
-
2018
- 2018-10-31 HK HK18113910.0A patent/HK1254820A1/zh unknown
- 2018-11-20 HK HK18114773.4A patent/HK1255637A1/zh unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11478548B2 (en) | 2015-07-08 | 2022-10-25 | The Johns Hopkins University | Marrow infiltrating lymphocytes (MILs) as a source of T-cells for chimeric antigen receptor (CAR) therapy |
Also Published As
Publication number | Publication date |
---|---|
HK1254820A1 (zh) | 2019-07-26 |
EP3313892A4 (en) | 2019-01-02 |
JP2018520679A (ja) | 2018-08-02 |
KR20180038447A (ko) | 2018-04-16 |
WO2017004150A1 (en) | 2017-01-05 |
CA2991040A1 (en) | 2017-01-05 |
AU2016285859A1 (en) | 2018-02-15 |
US20180185434A1 (en) | 2018-07-05 |
IL256643A (en) | 2018-02-28 |
EP3313892A1 (en) | 2018-05-02 |
CN108137707A (zh) | 2018-06-08 |
MA42272A (fr) | 2018-05-02 |
HK1255637A1 (zh) | 2019-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018000278A (es) | Terapia de receptores quimericos de puntos de control inmunitarios. | |
MX2021012720A (es) | Celulas t de receptor de antigeno quimerico co-estimulador que toman como diana a il13r-alfa-2. | |
MX2022013498A (es) | Receptores de antigenos quimericos dirigidos a her2. | |
PH12017501039A1 (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
MX2022003995A (es) | Antigeno quimerico y receptores de celulas t y metodos de uso. | |
PH12018500711A1 (en) | Anti-pd1 antibodies and methods of use | |
PH12017501521A1 (en) | Anti-dll3 chimeric antigen receptors and methods of use | |
MX2019009660A (es) | Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna. | |
PH12015502565B1 (en) | Anti-transferrin receptor antibodies and methods of use | |
IL246997A0 (en) | Antibodies against the extracellular domain of (muc1-c (muc1-c/ecd | |
NZ728674A (en) | Signalling system | |
MX2017007491A (es) | Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso. | |
WO2017066481A8 (en) | Chimeric antigen receptors containing a chlorotoxin domain | |
NZ741067A (en) | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use | |
MX2016010953A (es) | Proteinas de fc multimericas. | |
MX2016014862A (es) | Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2. | |
PH12017500825A1 (en) | Anti-cldn chimeric antigen receptors and methods of use | |
MX2017005977A (es) | Anticuerpos biespecificos y metodos de uso en oftalmologia. | |
MX2018001502A (es) | Receptor de antigeno quimerico y celulas t en las cuales se expresa el receptor de antigeno quimerico. | |
PH12019501605A1 (en) | Glucagon receptor binding proteins and methods of use thereof | |
MX2016012219A (es) | Agonistas de receptor fgf21 y usos del mismo. | |
MX2023006786A (es) | Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control. | |
WO2015035265A8 (en) | Induced expression of proteins in insect cells | |
MX2019002349A (es) | Anticuerpos inmunomoduladores biespecíficos que se fijan a receptores coestimuladores y de puntos de control. | |
EA201992003A1 (ru) | Применение антител к ctla-4 с повышенной adcc для усиления иммунного ответа на вакцину |